Compdrison of argatroban and hirudin for the reperfusion of thrombotic arterial occlusion by tissue plasminogen activator

Journal of Thrombosis and Thrombolysis

Volumn 6, Issue 2, 1998, Pages 103-108

  Boeve, Theodore J ^a   Reed, Guy L ^a   Carias De Oliveira, Nilto ^a   Titus, James ^a   Janssens, Stefan ^a   Giugliano, Robert P ^a   Torchiana, David ^a   Daggett, Willard ^a   Schwarz, Richard ^a   Jang, Ik Kyung ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Plasminogen activator; Reperfusion; Thrombin inhibitor

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; ARGATROBAN; HEPARIN; HIRUDIN; LYSINE ACETYLSALICYLATE; THROMBIN; TISSUE PLASMINOGEN ACTIVATOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ARTERY THROMBOSIS; ARTICLE; BLEEDING TIME; BLOOD CLOT LYSIS; BLOOD FLOW; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; FEMALE; FEMORAL ARTERY; HEART MUSCLE ISCHEMIA; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; RABBIT; REPERFUSION;

EID: 13144293098     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008889202725     Document Type: Article

References (27)

1. The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993;329: 1615-1622.
2. Cannon CP, McCabe CH, Diver DJ, et al. and the TIMI 4 Investigators. Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) 4 Trial. J Am Coll Cardiol 1994;24:1602-1610.
3. Neuhaus K-L, Von Essen R, Tebbe U, et al. Improved thrombolysis in acute myocardial infarction with frontloaded administration of alteplase: Results of the rt-PA-AP-SAC Patency Study (TAPS). J Am Coll Cardiol 1992; 19:885-891.
4. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indication for fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview of early mortality and major morbidity results from all randomized trials of more than 1000 patients. Lancet 1994;1:397-402.
5. Ohman EM, Califf RM, Topol EF, et al. and the TAMI Study Group. Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. Circulation 1993;82:781-791.
6. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673-682.
7. Eisenberg PR, Sherman LA, Schectman K, Perez J, Sobel B, Jaffe AS. Fibrinopeptide A: A marker of acute coronary thrombosis. Circulation 1985;71:912-918.
8. Eisenberg PR, Sherman LA, Jaffe AS. Paradoxical elevation of fibrinopeptide A after streptokinase: Evidence of continued thrombosis despite intense fibrinolysis. J Am Coll Cardiol 1987;10:527-529.
9. Hsia J, Hamilton WP, Kleiman N, Roberts R, Chaitman BR, Ross AM for the Heparin-Aspirin Reperfusion Trial (HART) Investigators. A comparison between heparin and low-dose aspirin as adjuctive therapy with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 1990;323:1433-1437.
10. Bleich SD, Nichols TC, Schumacher RR, Cooke DH, Tate DA, Teichman SL. Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction. Am J Cardiol 1990; 66:1412-1417.
11. Eitzman DT, Chi L, Saggan L, Schwartz RS, Luccesi BR, Fay WP. Heparin neutralization by platelet-rich thrombi. Role of platelet factor 4. Circulation 1994;89:1523-1529.
12. Berry CN, Girardot C, Lecoffre C, Lunven C. Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: Comparison with heparin and recombinant hirudin. Thromb Haemost 1994;72:381-386.
13. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990;86:385-391.
14. Zucker MB. Heparin and platelet function. Fed Proc 1977;36:47-49.
15. Rydel TJ, Ravichandran KG, Tulinsky A, Bode W, Huber R, Roitsch C, Fenton JW II. The structure of a complex of recombinant hirudin and human alpha-thrombin. Science 1990;249:277-280.
16. Markwardt F. Development of hirudin as an antithrombotic agent. Semin Thromb Hemost 1989;15:269-282.
17. Kikumoto R, Tamao Y, Tezuka T, et al. Selective inhibition of thrombin by (2R, 4R)-4-methyl-1-[N2-(3-methyl-1,2,3,4-tetrahydro-8-quinolinly)sulfonyl]-L- arginyl]-2-piperidinec arboxylic acid. Biochemistry 1984;23:85-90.
18. Lunven C, Gauffeny C, Lecoffre C, O'Brien DP, Roome NO, Berry CN. Inhibition by argatroban, a specific thrombin inhibitor, of platelet activation by fibrin clot-associated thrombin. Thromb Haemost 1996;75:154-160.
19. Eidt JF, Allison P, Noble S, et al. Thrombin is an important mediator of platelet aggregation in stenosed canine coronary arteries with endothelial injury. J Clin Invest 1989;84:18-27.
20. Jang IK, Gold HK, Leinbach RC, Fallon JT, Collen D. In vivo thrombin inhibition enhances and sustains arterial recanalization with recombinant tissue-type plasminogen activator. Circ Res 1990;67:1552-1561.
21. Haskel EJ, Prager NA, Sobel BE, Abendschein DR. Relative efficacy of antithrombin compared with antiplatelet agents in accelerating coronary thrombolysis and preventing early reocclusion. Circulation 1991;83:1048-1056.
22. Mruk JS, Zoldhelyi P, Webster MWI, et al. Does antithrombotic therapy influence residual thrombus after thrombolysis of platelet-rich thrombus? Effects of recombinant hirudin, heparin, or aspirin. Circulation 1996;93:792-799.
23. Antman EM for the TIMI 9B Investigators. Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial. Circulation 1996;94:911-921.
24. GUSTO IIb Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 1996;335:775-82.
25. Theroux P, Perez-Villa F, Waters D, Lesperance J, Shabani F, Bonan R. Randomized double-blind comparison of two doses of hirulog with heparin as adjunctive therapy to streptokinase to promote early patency of the infarct-related artery in acute myocardial infarction. Circulation 1995;91: 2132-2139.
26. Topol EJ, Fuster V, Harrington RA, et al. Recombinant hirudin for unstable angina pectoris. A multicenter, randomized angiographie trial. Circulation 1994;89:1557-1566.
27. Griffin JH. Blood coagulation. The thrombin paradox. Nature 1995;378:337-338.